Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Paredes

Showing results (271-280 of 309) with videos related to

Pageof 31
Sort By:
Cellular & Molecular Immunology|July 13, 2022
Author Correction to: SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cellsDaniel Perez-Zsolt, Jordana Muñoz-Basagoiti, Jordi Rodon, et al.
Cellular & Molecular Immunology|November 16, 2021
SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cellsDaniel Perez-Zsolt, Jordana Muñoz-Basagoiti, Jordi Rodon, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 8, 2025
Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trialAhmad Mourad, Gregory A Grandits, Lianne K Siegel, et al.
The New England Journal of Medicine|December 22, 2021
Early Remdesivir to Prevent Progression to Severe Covid-19 in OutpatientsRobert L Gottlieb, Carlos E Vaca, Roger Paredes, et al.
Clinical Trials (London, England)|October 11, 2021
Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3)Daniel D Murray, Abdel G Babiker, Jason V Baker, et al.
Lancet (London, England)|February 24, 2023
Mpox in people with advanced HIV infection: a global case seriesOriol Mitjà, Andrea Alemany, Michael Marks, et al.
Nature Communications|February 24, 2025
Plasma exchange therapy for the post COVID-19 condition: a phase II, double-blind, placebo-controlled, randomized trialSergio España-Cueto, Cora Loste, Gemma Lladós, et al.
American Journal of Respiratory and Critical Care Medicine|May 17, 2022
Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess RecoveryDavid J Douin, Lianne Siegel, Greg Grandits, et al.
Medrxiv : the Preprint Server for Health Sciences|November 20, 2020
Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3)Daniel D Murray, Abdel G Babiker, Jason V Baker, et al.
The Journal of Infectious Diseases|October 6, 2022
Limited Humoral and Specific T-Cell Responses After SARS-CoV-2 Vaccination in PWH With Poor Immune ReconstitutionSusana Benet, Oscar Blanch-Lombarte, Erola Ainsua-Enrich, et al.
Pageof 31

Showing results (271-280 of 309) with videos related to

Sort By:
Pageof 31
Cellular & Molecular Immunology|July 13, 2022
Author Correction to: SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cellsDaniel Perez-Zsolt, Jordana Muñoz-Basagoiti, Jordi Rodon, et al.
Cellular & Molecular Immunology|November 16, 2021
SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cellsDaniel Perez-Zsolt, Jordana Muñoz-Basagoiti, Jordi Rodon, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 8, 2025
Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trialAhmad Mourad, Gregory A Grandits, Lianne K Siegel, et al.
The New England Journal of Medicine|December 22, 2021
Early Remdesivir to Prevent Progression to Severe Covid-19 in OutpatientsRobert L Gottlieb, Carlos E Vaca, Roger Paredes, et al.
Clinical Trials (London, England)|October 11, 2021
Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3)Daniel D Murray, Abdel G Babiker, Jason V Baker, et al.
Lancet (London, England)|February 24, 2023
Mpox in people with advanced HIV infection: a global case seriesOriol Mitjà, Andrea Alemany, Michael Marks, et al.
Nature Communications|February 24, 2025
Plasma exchange therapy for the post COVID-19 condition: a phase II, double-blind, placebo-controlled, randomized trialSergio España-Cueto, Cora Loste, Gemma Lladós, et al.
American Journal of Respiratory and Critical Care Medicine|May 17, 2022
Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess RecoveryDavid J Douin, Lianne Siegel, Greg Grandits, et al.
Medrxiv : the Preprint Server for Health Sciences|November 20, 2020
Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3)Daniel D Murray, Abdel G Babiker, Jason V Baker, et al.
The Journal of Infectious Diseases|October 6, 2022
Limited Humoral and Specific T-Cell Responses After SARS-CoV-2 Vaccination in PWH With Poor Immune ReconstitutionSusana Benet, Oscar Blanch-Lombarte, Erola Ainsua-Enrich, et al.
Pageof 31